AstraZeneca joins Moderna and Pfizer in combating COVID-19
The race for finding a viable COVID-19 vaccine intensified in the past couple of weeks. After Moderna and Pfizer announced that their experimental COVID-19 vaccines have over 90% effectiveness in preventing the infection, another company reported impressive results.
AstraZeneca stated that according to the early-stage trials, its vaccine triggers an immune response among adults. The data collected from 560 volunteers revealed that the adults aged between 18 and 55 and those over 56 had a similar immune response.
“We’re really delighted with the results,” stated Professor Andrew Pollard, Head of Oxford’s vaccine trial team. The vaccine - ChAdOx1 nCoV-19 showed a response 14 days after the first administrated dose, while antibodies appeared 28 days after the second dose, which is considered a booster.
As stated before, other pharma companies announced their vaccines’ effectiveness. Pfizer, whose vaccine is 95% effective in preventing COVID-19 infection, is said to file for an emergency use application to the FDA later today. Moderna is expected to do the same in the following days.
In pre-market trading, AstraZeneca stock price gained 1.80%.
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.
Key Way Markets Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.